FAST FACTS
FOUNDER(S):
Herb Boyer
Robert Swanson
INNOVATION(S):
Biotechnology/Pharmaceuticals
Cancer Therapies/Tests
EMPLOYEES:
11000
HEADQUARTERS:
South San Francisco, CA
FOUNDED:
1976
REVENUE:
$13.4 billion FY08
TSC MEMBER INSTITUTION(S):
University of California, San Francisco
Stanford University
FUNDING AGENCY(S):
National Institutes of Health
National Science Foundation
STATUS:
Public
|
GENENTECH, INC.
IN BUSINESS FOR LIFE
ABOUT THE COMPANY:
The story of how Herbert Boyer, a faculty member at University of California, San Francisco (UCSF) and Stanford University professor Stanley Cohen discovered recombinant DNA technology — over pastrami and corned beef sandwiches at a convention in Hawaii — has become the stuff of legends. The subsequent pioneering university-based research was supported by grants from the National Institutes of Health and the National Science Foundation and opened the door to the whole world of genetic engineering.
Boyer went on to establish Genentech, a leading biotechnology company. Established in 1976, it played a significant role in the formation of the biotechnology industry. Genentech develops and manufactures drugs for asthma, rheumatoid arthritis, blood clots, and a variety of cancers. In March 2009, Genetech became a wholly owned member of the Roche Group.
UNIVERSITY-BASED RESEARCH CONNECTION:
Genentech was established by Herbert Boyer, a faculty member at University of California, San Francisco, in collaboration with Robert Swanson of Kleiner Perkins, a venture capital partnership. Genentech capitalized on recombinant DNA technology developed by Boyer at UCSF and Stanley Cohen at Stanford University.
ROLE OF FEDERAL RESEARCH FUNDING:
Boyer and Cohen’s pioneering research on recombinant DNA technology was supported by grants from the National Institutes of Health and the National Science Foundation.
 Read The Full Report Here
|
Printer-Friendly Version
GENENTECH, INC.